title: C-reactive protein is elevated 30 years after eclamptic pregnancy.
abstract: Women with a history of preeclampsia or eclampsia (seizure during preeclamptic pregnancy) are at increased risk for cardiovascular disease after pregnancy for reasons that remain unclear. Prospective studies during pregnancy suggest that inflammation, dyslipidemia, and insulin resistance are associated with increased risk of preeclampsia. Elevated serum C-reactive protein (CRP >3 mg/L) is an indicator of inflammation and cardiovascular risk. We hypothesized that Icelandic postmenopausal women with a history of eclampsia would manifest higher concentrations of serum CRP than Icelandic postmenopausal controls with a history of uncomplicated pregnancies. We also asked whether elevated CRP is associated with the dyslipidemia and insulin resistance previously identified in this cohort. CRP, measured by high-sensitivity enzyme-linked immunoassay, was higher in women with prior eclampsia (n=25) than controls (n=28) (median mg/L [interquartile range]: 9.0 [0.9 to 13.2] versus 2.0 [0.3 to 5.1]; P<0.03). This difference remained significant after adjustment for body mass index, smoking, hormone replacement, and current age. Women with prior eclampsia clustered into either high CRP (range 8.97 to 40.6 mg/L, n=13) or lower CRP (median 1.0, range 0.05 to 3.77, n=12) subsets. The prior eclampsia/high CRP subset displayed significantly elevated systolic blood pressures, lower high-density lipoprotein (HDL) cholesterol, higher apolipoprotein B, and higher fasting insulin and homeostasis model of insulin resistance (HOMA) values compared to controls, whereas the prior eclampsia/low CRP subset differed from controls only by marginally increased apolipoprotein B. The triad of inflammation, low HDL, and insulin resistance may elevate risk for both preeclampsia/eclampsia and cardiovascular disease in later life.
authors.affiliation: Magee-Womens Research Institute and Department of Obstetrics and Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pa., USA.
authors.forename: Carl A
authors.initials: CA
authors.lastname: Hubel
authors.forename: Robert W
authors.initials: RW
authors.lastname: Powers
authors.forename: Sunna
authors.initials: S
authors.lastname: Snaedal
authors.forename: Hilary S
authors.initials: HS
authors.lastname: Gammill
authors.forename: Roberta B
authors.initials: RB
authors.lastname: Ness
authors.forename: James M
authors.initials: JM
authors.lastname: Roberts
authors.forename: Reynir
authors.initials: R
authors.lastname: Arngrímsson
mesh_terms: D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism*; D008076:Cholesterol, HDL / Q000097:blood; D050171:Dyslipidemias / Q000453:epidemiology / Q000276:immunology / Q000378:metabolism; D004461:Eclampsia / Q000453:epidemiology / Q000276:immunology* / Q000378:metabolism; D005260:Female; D006801:Humans; D006973:Hypertension / Q000453:epidemiology / Q000276:immunology* / Q000378:metabolism; D007249:Inflammation / Q000453:epidemiology / Q000276:immunology* / Q000378:metabolism; D007333:Insulin Resistance; D008875:Middle Aged; D011225:Pre-Eclampsia / Q000453:epidemiology / Q000276:immunology* / Q000378:metabolism; D011247:Pregnancy; D012307:Risk Factors; D013997:Time Factors
chemical_list: D015415:Biomarkers; D008076:Cholesterol, HDL; D002097:C-Reactive Protein